0000000000558781
AUTHOR
Savoca G
Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study
Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …
Confronti dosimetrici tra due tecniche radioterapiche a modulazione di intensità nei trattamenti stereotassici polmonari ipofrazionati
La radioterapia stereotassica extra-cranica (Stereotactic Body Radiation Therapy) consente di somministrare una dose ablativa ad un volume bersaglio non encefalico mediante un numero ridotto di frazioni. La riduzione nel numero di frazioni comporta necessariamente un aumento della precisione ed accuratezza in tutte le fasi del trattamento, dalla simulazione CT alla pianificazione ed all’erogazione della dose terapeutica. Dal punto di vista dosimetrico i trattamenti SBRT sono caratterizzati innanzitutto da un elevato grado di conformazione e soprattutto dalla presenza di gradienti di dose particolarmente ripidi necessari per minimizzare la dose ai tessuti sani circostanti ed agli organi a ri…
Paradoxical arterial priapism: post-traumatic monolateral low penile perfusion and curvature associated to contro-lateral arterious-cavernous aceration and fistulization.
Poster for IX Congress of the European Society for Sexual Medicine. Vienna, Dicember 3th – 6th 2006
Incidental ultrasound findings in a great population of sub-fertile patients: our experience and description of a paradoxical oncological disease.
Poster for XXXI Congress of the European Society of Urology. Paris, 28-29 Aprile 2006